Antimicrobial resistance (AMR) has often been described as a "silent pandemic"—one that doesn't dominate daily headlines but continues to reshape healthcare in profound ways. Every day, clinical laboratories generate the data that guide physicians toward the right therapy, help infection prevention teams identify emerging threats, and support antimicrobial stewardship efforts designed to preserve the effectiveness of the drugs we still have. As AMR continues to evolve, so too does the laboratory's role.
This month's MLO SOI survey offers a snapshot of where laboratories stand today. Many respondents reported performing large volumes of antimicrobial resistance testing, while others acknowledged they don't track testing volume or are unsure how much testing is being performed. That finding alone is telling. It reflects the reality that AMR programs vary tremendously depending on laboratory size, resources, patient populations, and available technology. Yet regardless of these differences, every laboratory contributes valuable information to the broader effort to detect and contain resistant organisms.
Our survey also highlights a profession in transition. Traditional culture-based antimicrobial susceptibility testing remains the backbone of microbiology laboratories, but molecular resistance testing continues to gain momentum. Rapid PCR, automated susceptibility systems, MALDI-TOF, and emerging rapid phenotypic methods are helping laboratories shorten turnaround times and provide clinicians with answers sooner than ever before. At the same time, laboratorians recognize that speed alone is not enough. As several experts in this issue note, genotypic and phenotypic testing answer different—but equally important—clinical questions. The future will depend on integrating these approaches to provide faster, more complete, and more actionable information.
Recent scientific literature suggests that the next phase of the fight against AMR will require an even broader perspective. Researchers increasingly emphasize that combating resistance will depend not only on discovering new antibiotics but also on advancing rapid diagnostics, artificial intelligence-assisted drug discovery, bacteriophage therapy, antimicrobial peptides, CRISPR-based technologies, and other innovative therapeutic approaches. Equally important is the continued expansion of antimicrobial stewardship in healthcare organizations.
Perhaps the most encouraging message emerging from both our survey and the latest research is that the laboratory is becoming even more central to the solution. The value of diagnostic testing is no longer measured solely by identifying an organism. Increasingly, laboratories are expected to answer a more complex set of questions: Is the infection bacterial or viral? Which resistance mechanisms are present? Which therapy is most likely to succeed? How should this information inform stewardship efforts across an entire healthcare system?
Those are ambitious expectations—but they also represent an extraordinary opportunity for our profession. As diagnostic technologies continue to advance and laboratory data become increasingly integrated into clinical decision-making, laboratorians will remain indispensable partners in protecting both today's patients and tomorrow's antibiotics. That makes the work happening in laboratories every day more important than ever.
I welcome your comments and questions — please send them to me at [email protected].
